查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138299

全球左心耳 (LAA) 设备市场 - 2022-2029

Global Left Atrial Appendage Devices (LAA) Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

由于心律失常患者的增加，预计市场扩张

预计左心耳 (LAA) 设备市场将在全球新兴经济体实现两位数的增长。人们认识到，高增长率是由于患有心房颤动和其他心律失常的患者数量不断增加。发达国家房颤的高风险将导致对左心耳的需求增加，这将推动左心耳（LAA）器械市场的增长。此外，在预测期内，心律失常、糖尿病和高血压的患病率预计将增加对左心耳 (LAA) 设备市场的需求。

此外，政府对提高对心律失常的认识的重点有望促进左心耳 (LAA) 设备市场。心律失常的主要患者群体显着增加了 LAA（左心耳）装置的采用率。为了预防中风风险和减少血栓，对左心耳的需求有所增加。

另一方面，左心耳 (LAA) 设备的高成本预计将阻碍全球左心耳 (LAA) 设备市场。此外，由于与左心耳相关的高成本，人们更喜欢更实惠的替代解决方案。因此，这一因素将阻碍预测期内市场的增长。此外，左心耳报销政策的差异也有望减缓全球市场的增长。

内容

第一章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按产品划分的市场细分
  • 按程序划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 约束因素
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章按药物类别类型

  • 心内膜
  • 心外膜

第 8 章技术

  • 经皮
  • 外科手术

第 9 章，最终用户

  • 医院
  • 门诊手术中心
  • 心臟诊所

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Boston Scientific Corporation
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • AtriCure
  • Abbott
  • Biosense Webster
  • Lifetech Scientific
  • SentreHEART
  • Append Medical
  • Cardia
  • Johnson & Johnson
  • Occlutech

第13章 DataM

简介目录
Product Code: DMHCIT2956

Market Overview

Left atrial appendage devices (LAA) market was valued at USD 490 million in 2021. It is forecasted to reach USD million by 2029, growing at a CAGR of 20.2% during the forecast period (2022-2029).

Left atrial appendages (LAA) are the small, ear-shaped sac in the left atrium's muscle wall. The left atrial appendage is a minimally invasive technique that supports lowering the risk of stroke. A high-risk stroke arises due to atrial fibrillation. Left atrial appendage (LAA) devices such as the Amplatzer plug device and watchman device reduce blood clots' probability and prevent heart stroke. The device transplantation is usually achieved under anesthesia with trans-esophageal echo guidance. The growing elderly population and the rising occurrence of atrial fibrillation worldwide are key factors fuel the growth of the left atrial appendage devices (LAA) Market.

Market Dynamics: An increase in the number of arrhythmias patients suffering expected to drive market growth.

The left atrial appendage devices (LAA) Market is estimated to grow with double-digit growth in the developing economies across the globe. The high growth rate is recognized by the continuously growing number of patients suffering from atrial fibrillation and other arrhythmias. There is a high risk for atrial fibrillation in developed countries, which will boost the demand for left atrial appendage devices, which will boost the growth of the left atrial appendage devices (LAA) Market. Furthermore, the growing prevalence of cardiac rhythm disorders, diabetes, and high blood pressure is expected to increase the demand for the left atrial appendage devices (LAA) Market over the forecast period.

Moreover, increasing the government's focus on raising awareness about cardiac arrhythmias will contribute to the left atrial appendage devices (LAA) market. The adoption rate of the LAA (left atrial appendage) devices has increased significantly due to a key patient pool suffering from cardiac rhythm abnormalities. To prevent stroke risk and reduce blood clots, the demand for left atrial appendage devices increased.

On the contrary, the high cost of left atrial appendage (LAA) devices is expected to hamper the global left atrial appendage devices (LAA) Market. Moreover, due to the high cost associated with left atrial appendage devices, people prefer alternative solutions that are more affordable. Thus, this factor hinders the market's growth over the forecast period. Further, the disparity in left atrial appendage devices' reimbursement policies is also expected to stagnant the global market's growth.

Market Segmentation: Hospitals segment accounted for the highest share in global left atrial appendage devices (LAA) market.

The hospital segment is projected to dominate the left atrial appendage devices (LAA) Market due to the increasing numbers of heart-related disease cases across the globe, which propels the demand for specialty hospitals to treat heart-related diseases. Moreover, improving and advancing medical infrastructure is estimated to boost left atrial appendage devices in hospitals. Health spending in the U.S. is projected to have grown 4.2% to $4.3 trillion in 2021 as compared to a growth surge of 9.7% in 2020, according to the data published by actuaries at the Centers for Medicare and Medicaid Services.

The ambulatory surgical center segment is estimated to hold a significant share in the global left atrial appendage devices (LAA) market and grow with a healthy CAGR over the forecast period. Moreover, ambulatory surgical centers have a low cost compared to hospitals. They have minimal risk of infection, estimated to enhance the left atrial appendage devices (LAA) Market.

The epicardial left atrial appendage devices segment is expected to grow with a significant growth rate during the forecast timeframe due to the increasing adoption of these products in developed economies across the globe. Moreover, the epicardial left atrial appendage device can negate the need to implant a permanent device. Also, the epicardial device does not require anticoagulation post-procedure. Thus, due to these several benefits of epicardial left atrial appendage devices, the Market is estimated to create lucrative growth opportunities during the forecast timeframe.

Geographical Penetration: North America is the dominating region during the forecast period.

North America is projected to hold the largest share in the left atrial appendage devices (LAA) market due to the increasing number of atrial fibrillation cases. The increasing atrial fibrillation population in the United with the increasing geriatric population across the nation drives the market growth. Atrial Fibrillation is expected to cause heatstroke, and subsequently, left atrial appendage management is of extreme importance. Additionally, novel technologies are being launched in the market, which is estimated to raise these devices' adoption across the region. US census projections for the next 50 years estimate that about 3 million Americans will have atrial fibrillation by the year 2020, increasing to 5.6 million by the year 2050, with more than half affected age 80 or older.

Competitive Landscape:

The left atrial appendage devices (LAA) market is moderately fragmented with the presence of regional as well as global players. Some of the key players in the growth of the market include Boston Scientific Corp., AtriCure, Abbott, Biosense Webster, Lifetech Scientific, SentreHEART and Append Medical among others. The key players are executing several growth strategies, such as product launches, acquisitions, and collaborations, which are expected to fuel the global left atrial appendage devices (LAA) market. In July 2020, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. This device helps to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative therapy. In April 2022, Abbott announced the U.S. availability of its Amplatzer steerable delivery sheath device. It is used with the company's Amplatzer Amulet left atrial appendage (LAA) occluder is used to treat people with atrial fibrillation (AFib) to reduce the risk of ischaemic stroke. U.S. physicians now have more flexibility and precise placement when implanting the Amulet device in simple and complex anatomies.

COVID-19 Impact: Positive impact on the global left atrial appendage devices (LAA) market

The left atrial appendage device (LAA) market is estimated to experience a surge in the left atrial appendage market's growth rate. Several countries' governments and private organizations are taking initiatives to create awareness among the population during this pandemic. These factors are projected to increase the growth of the left atrial appendage market. Along with this factor, manufacturers focused on developing new products to gain a strong position in the global market during a pandemic. Due to the pandemic, there is a rise in the number of ambulatory clinical centers globally. The advancement of products by key manufacturers is expected to boost the growth left atrial appendage market.

The global left atrial appendage devices (LAA) market report would provide an access to approximately 61 market data tables, 50 figures and 170 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Procedure
  • 3.3. Market Snippet by End-Use
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Drug Class Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Segment
    • 7.1.2. Market attractiveness index, By Product Segment
  • 7.2. Endocardial *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Epicardial

8. By Procedure

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Procedure Segment
    • 8.1.2. Market attractiveness index, By Procedure Segment
  • 8.2. Percutaneous*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Surgical

9. By End Use

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By End Use Segment
    • 9.1.2. Market attractiveness index, By End Use Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Heart Clinics

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Use

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Boston Scientific Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AtriCure
  • 12.3. Abbott
  • 12.4. Biosense Webster
  • 12.5. Lifetech Scientific
  • 12.6. SentreHEART
  • 12.7. Append Medical
  • 12.8. Cardia
  • 12.9. Johnson & Johnson
  • 12.10. Occlutech
  • List not Exhaustive*

13. DataM

  • 13.1. Appendix
  • 13.2. About us and services
  • 13.3. Contact us